



International Journal of Research Publication and Reviews

Journal Homepage: www.ijrpr.com ISSN 2582-7421

CAR-T Cell Therapy: Transforming Cancer Care, One Living Cell at a Time.

Dhruvi D Shetty, Dr. Dhanya.T. Bappanad*, Dr. A. R. Shabaraya*

Department of Pharmacy practice, Srinivas College of Pharmacy, Valachil, post Farangipete, Mangalore-574143, Karnataka, India.
EMAIL ID:dhruvishetty80@gmail.com

ABSTRACT:

Cancer is still a major global health problem with increased incidence and mortality rates year on year. Traditional treatments like surgery, radiation and chemotherapy often have limitations, particularly for metastatic or recurrent cancers. CAR-T cell therapy is a revolutionary cancer treatment method that effectively treats blood cancers like B-ALL, MM, and NHL. It uses a customized chimeric antigen receptor and T cell receptor to identify tumor antigens. The review describes a next-generation strategy for T cell editing to design artificial receptors in an attempt to improve remission rates in hematologic malignancies, specifically ALL and large B cell lymphoma. This current review is directed towards overcoming these barriers through the engineering of CAR T cells with enhanced resilience and multi-antigen targeting. CAR T-cell techniques utilize universal donor CAR T cells and CRISPR-Cas9 to reduce manufacturing costs and risk, and are being combined with immune checkpoint inhibitors for improved outcomes. Supporting these findings are literature reviews which includes databases such as PubMed and Scopus, to show the therapy's potential and ongoing efforts to personalize the therapy for different cancers. More research is needed to overcome limitations and further benefit from CAR T-cell therapy. Cytokine release syndrome and neurotoxicity are common and managed with tocilizumab and supportive care. CRISPR-Cas9 is being utilized to create universal CAR T cells to reduce graft-versus-host disease and make treatment more accessible. CAR T-cell therapy in the future looks promising to circumvent challenges with solid tumors through nanotechnology-based approaches. Accessibility can be facilitated and risk avoided through CRISPR-Cas9, and methods to circumvent T-cell exhaustion and antigen escape must be explored.

Keywords: CAR T-cell therapy, hematologic malignancies, solid tumors, cytokine release syndrome, tumor microenvironment, universal CAR T-cells.

INTRODUCTION:

Cancer is a serious health problem with increasing incidence and mortality rates year by year^[1]. However, several conventional treatments and cytotoxic immunotherapies have been developed and are available^[2], but traditional approaches, including surgery, radiation therapy, and chemotherapy, have major limitations. However, poor prognoses prevail in many patients with metastatic or recurrent cancer. Since the past decade, with the development of advanced cancer molecular medicine and immuno-oncology, targeted therapy has been developed and precision medicine has appeared, which is more specific and less toxic than before for the treatment of cancer^[1]. Due to the complexity of tumors and the number of genetic and cellular factors that are involved in tumorigenesis and metastasis, there is an urgent need for innovative immunotherapies that are able to target tumors on both the cellular and genetic level^[2]. A chimeric antigen receptor (CAR)-T cell therapy is a breakthrough in cancer treatment that has been so successful especially in hematological malignancies like B cell acute lymphoblastic leukemia (B ALL), multiple myeloma (MM) and non Hodgkin lymphoma (NHL)^[3]. The currently approved CAR T cell therapies target the B cell maturation antigen (BCMA) for multiple myeloma, and the B cell antigen CD19 for various lymphoid malignancies including B cell leukemias and some types of lymphomas. CAR T cell therapy, however, has shown promising results in hematological cancers, and may be applicable in other types of cancers^[1]. CAR T cell therapies have been approved by the U.S. Food and Drug Administration (FDA) to date for treating B cell acute lymphoblastic leukemia (B ALL), diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and multiple myeloma (MM)^[4]. CAR-T cell therapies targeting CD19 and B cell maturation antigen (BCMA) are now approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory B cell cancers^[3]. Chimeric antigen receptor (CAR) is a genetically engineered receptor with two components: an antigen binding domain derived from a monoclonal antibody and T cell receptor (TCR) signaling domain. The use of CAR-T cell therapy is an innovative approach to T cell engineering where T cells are collected from a patient's blood and modified in vitro to express synthetic receptors that target tumor antigens^[2]. Through these receptors the direct identification of tumor antigens can be accomplished without involvement of the major histocompatibility complex. This therapy has been successful over recent years, attaining remission rates of up to 80% in hematologic cancers, especially in ALL and large B cell lymphoma^[2]. Six CAR-T cell therapies had been approved by April 2023 and showed extraordinary efficacy in patients with B cell malignancies and multiple myeloma. Nevertheless, significant obstacles in CAR-T cell therapy include cytokine release syndrome and immune effector cell associated neurotoxicity. These complications are very severe and their severity is closely correlated with the tumor burden before treatment, the worse the tumor burden the worse the side effects^[5]. The research also indicates that early initiation

of CAR T cell therapy when tumor burden is low or the use of a debulking strategy before infusion may lessen the adverse event. But CAR T cell therapy is not only expensive but also is not very effective against solid tumors^[5]. This therapy has been an amazing success in treating hematologic cancers, but that comes with a heavy price tag in the form of severe adverse effects, such as cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS). CRS is usually driven by cytokines IL-1 and IL-6 and can lead to symptoms such as fever, hypotension, and other systemic reactions.

In order to overcome this, the FDA approved the use of the humanized anti IL-6 receptor antibody tocilizumab in 2017 to prevent CRS and neurotoxicity due to CAR T cell therapy^[5]. Despite its success in hematologic malignancies, CAR T cell therapy has been unsuccessful in treating solid tumors, which represent more than 90% of adult tumors and over 30% of pediatric tumors. The biggest challenge of solid tumors is an immunosuppressive tumor microenvironment (TME) and the lack of tumor specific target^[5]. However, CAR T cells have shown the potential to help patients unresponsive to multiple prior treatments. However, despite this, many patients keep experiencing either primary or secondary resistance to this treatment. CAR T cells themselves, the tumor microenvironment, or the tumor cells engaged can drive resistance^[4]. The issue of tumor resistance to CAR constructs directed against a single antigen is a very significant challenge for CAR T cell therapy. However, high initial response rates can be achieved using CAR-T cells that target a single antigen, but many malignant cells of treated patients develop a partial or complete loss of expression of the target antigen, which is termed antigen escape^[6]. In order to address this issue, and due to the variety of available biomarkers and the complicated structure of biomarkers, multiple generations of CAR models have been developed^[2].

OBJECTIVES: -

1. Evaluate the efficacy of CAR T-cell therapy in treating hematologic malignancies.
2. Explore advancements in CAR T-cell therapy, including universal CAR T-cell approaches and combination therapies, to enhance efficacy and safety.
3. Identify and analyze the challenges hindering the application of CAR T-cell therapy and discuss the adverse effects associated with CAR T-cell therapy

METHODOLOGY: -

This narrative review aims to comprehensively analyze the current landscape of Chimeric Antigen Receptor (CAR) T-cell therapy, focusing on its clinical applications, challenges, and future prospects. A systematic literature search was conducted across electronic databases, including PubMed, Scopus, and Web of Science, covering publications up to March 2025. Keywords and Medical Subject Headings (MeSH) terms such as “CAR T-cell therapy,” “chimeric antigen receptor,” “hematologic malignancies,” “solid tumors,” “clinical trials,” “adverse effects,” “cytokine release syndrome,” “immune effector cell-associated neurotoxicity syndrome,” “tumor microenvironment,” “antigen escape,” and “combination therapy” were utilized to identify relevant studies.

INCLUSION CRITERIA: - Original research articles, clinical trials, meta-analyses, and systematic reviews published in peer-reviewed international journals, focusing on CAR T-cell therapy's efficacy, safety, and application in various cancer types

EXCLUSION CRITERIA:- Involved non-English publications, case reports, conference abstracts, and studies lacking substantial data on clinical outcomes.

RESULT AND DISCUSSION: -

Blood Cancers have responded well to CAR T-cell therapy. Acute lymphoblastic leukemia and non Hodgkin lymphomas among other relapsed or refractory B cell cancers have responded well with CAR T-cell products approved by FDA. In clinical studies, remission rates have been high; some patients have responded durably for several years. Solid tumor CAR T cell therapy: Since CAR T cell therapy has been successful in treating blood cancers, it poses difficulties in solid tumors. Two main challenges are the immunosuppressive TME and the dearth of tumor specific antigens. Researchers are developing CAR T-cells to target several antigens to lower the possibility of escape from tumor mechanisms and escape from TME, so overcoming these obstacles. Typical Negative Effects Typical negative impacts of CAR T-cell therapy include CRS and neurotoxicity. Symptomatic with fever and low blood pressure, CRS affects many patients which are usually managed with cytokine inhibitors like tocilizumab. Careful monitoring and supportive treatment is needed for neurotoxicity, which can be mild confusion to severe encephalopathy. Recent Advances in CAR T Cell Therapy: Recent innovations in CAR T cell therapy have been directed towards improving efficacy and accessibility. To overcome the limitations of autologous therapies such as manufacturing delays and high cost, we are developing universal CAR T cells from healthy donors. This puts CRISPR-Cas9 gene editing technology to use to make UCAR T cells with lower risk of graft versus host disease. In addition, combination therapies using CAR T-cell therapy in conjunction with immune checkpoint inhibitors or other treatments are being investigated as a means to improve outcomes, especially in solid tumors.

Efficacy & Advances in CAR-T Therapy

CAR-T therapy has shown high efficacy in hematological malignancies, particularly B-cell leukemias and lymphomas, leading to durable remissions (Maude SL, 2014; Lu J, 2022; Pasqui DM, 2022). Next-generation CAR-T cells, including universal (allogeneic) CAR-Ts, are being developed to overcome donor restrictions and reduce costs (Lin H, 2021; De Marco RC, 2023). Nanotechnology-assisted CAR-T therapy aims to improve tumor targeting, reduce toxicity, and enhance drug delivery (Wang Y, 2024). Combination therapies integrating checkpoint inhibitors, small molecules, and other immunotherapies are showing promise in boosting CAR-T effectiveness and reducing relapse (Al-Haideri M, 2022; Dabas P, 2023). Recent research is also focused on improving CAR-T expansion and persistence within the body to extend therapeutic effects (Ahmad A, 2020; Sermer D, 2019).

Challenges & Mechanisms of Resistance

Tumor antigen escape remains a major challenge, where cancer cells lose or alter target antigens to evade CAR-T cells (Majzner RG, 2018; Gu T, 2022). T-cell exhaustion occurs when CAR-T cells become dysfunctional over time, reducing efficacy. Strategies such as metabolic reprogramming and immune checkpoint blockade are being explored to rejuvenate exhausted T cells (Yin X, 2023; Larson RC, 2021). The tumor microenvironment (TME) suppresses CAR-T function by releasing inhibitory signals that impair immune cell activity. Research into modifying CAR-T cells to resist TME suppression is ongoing (Kankeu Fonkouda LA, 2022; Al-Haideri M, 2022). Dual-targeting CARs that recognize multiple antigens are being tested to reduce antigen escape and improve effectiveness against diverse tumor populations (Sterner RC, 2021; Flügge CL, 2023).

Toxicity & Side Effects

Cytokine Release Syndrome (CRS) is the most common CAR-T toxicity, ranging from mild flu-like symptoms to life-threatening inflammation. IL-6 inhibitors (tocilizumab) and corticosteroids are the main treatments (Miao L, 2021; Schubert ML, 2020). Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) affects cognitive functions, sometimes leading to seizures or coma. Close monitoring and steroid treatment are recommended (Grant SJ, 2022; Rejeski K, 2024). On-target, off-tumor toxicity occurs when CAR-T cells attack healthy tissues expressing the same antigen as the tumor, a significant concern in solid tumors (Flügge CL, 2023; Chohan KL, 2023). Hematological toxicity, including prolonged low blood counts, is common after CAR-T therapy, increasing infection risks (Bupha-Intr O, 2021; Rejeski K, 2024).

CAR-T Therapy for Solid Tumors

Unlike hematological cancers, solid tumors present unique challenges due to poor CAR-T cell infiltration, antigen heterogeneity, and an immunosuppressive tumor microenvironment (Maalej KM, 2023; Ma S, 2019; Kankeu Fonkouda LA, 2022). Armored CAR-T cells, engineered to produce immune-boosting cytokines, are being investigated to improve responses against solid tumors (Flügge CL, 2023; Lemoine J, 2021). Novel strategies like CAR-T combined with checkpoint inhibitors and radiation therapy are being tested to overcome resistance in solid tumors (Almasbak H, 2016; Ahmad A, 2020).

Relapse & Resistance Mechanisms

CAR-T therapy relapse occurs in many patients, often due to antigen escape or lack of CAR-T persistence (Gu T, 2022; Akhoundi M, 2021). Immunosuppressive factors within the TME, such as regulatory T cells and myeloid-derived suppressor cells, hinder CAR-T activity, prompting research into combination approaches (Kankeu Fonkouda LA, 2022; Bupha-Intr O, 2021). Overcoming resistance using gene-editing (CRISPR) and bispecific CAR-T approaches is an active area of research (Lin H, 2021; De Marco RC, 2023).

Future Directions & Innovations

Next-generation CAR-T cells (fourth and fifth-generation CARs) are being developed to include additional immune-enhancing functions, improving persistence and efficacy (Larson RC, 2021; Kallam A, 2019). Gene-editing tools like CRISPR are improving CAR-T cell engineering, allowing for better tumor recognition and lower side effects (Lin H, 2021). Automated manufacturing of CAR-T therapy is expected to lower costs and make the treatment more accessible (De Marco RC, 2023; Sermer D, 2019). CAR-T cell therapy is expanding beyond cancer, with potential applications in autoimmune diseases and infections (Chohan KL, 2023; Wang Y, 2024). CAR-T cell therapy has revolutionized cancer treatment, particularly for hematologic malignancies, but challenges remain in solid tumors, toxicity management, and resistance mechanisms. Innovative approaches like universal CARs, gene editing, nanotechnology, and combination therapies are being actively researched to improve efficacy, reduce relapse, and expand CAR-T applications.

CONCLUSION: -

CAR T-cell therapy represents a significant advancement in cancer treatment, particularly for hematologic malignancies. Ongoing research and clinical trials are crucial to overcoming current limitations and expanding the applicability of CAR T-cell therapy across various cancer types.

ACKNOWLEDGEMENTS

I am thankful to Research guide, Principal and Management of Srinivas college of Pharmacy, Mangalore for providing all the necessary facilities to carry out this review work.

REFERENCES:

1. Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. *Mol Cancer*. 2023;22(1):20.
2. Almasbak H, Aarvak T, Vemuri MC. CAR T cell therapy: A new era for cancer treatment. *Scand J Immunol*. 2016;84(4):283-93.
3. Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT, et al. CAR-T cell combination therapy: the next revolution in cancer treatment. *Cancer Cell Int*. 2022;22(1):365.
4. Lemoine J, Ruella M, Houot R. Born to survive: how cancer cells resist CAR T cell therapy. *J Hematol Oncol*. 2021;14(1):199.
5. Zhu D, Xu Y, Wang X, Zhang X, Lu Y, Li L, et al. From bench to bedside: the history and progress of CAR T cell therapy. *Front Immunol*. 2023;14:1188049.
6. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. *Blood Cancer J*. 2021;11(4):69.
7. Miao L, Zhang Z, Ren Z, Li Y. Reactions Related to CAR-T Cell Therapy. *Front Immunol*. 2021 Apr 28;12:663201.
8. Schubert M L, Schmitt M, Wang L, Ramos C A, Jordan K, Tidow C M, et al. Side effect management of chimeric antigen receptor (CAR) T-cell therapy. *Annals of onco*. 2020 Oct 21; 32(1): 1-48.
9. Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. *Mol Ther Oncolytics*. 2022 Mar 19;25:69-77.
10. Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, Giri S. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. *Transplant Cell Ther*. 2022 Jun;28(6):294-302.
11. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med*. 2014 Oct 16;371(16):1507-17.
12. Chohan, K.L., Siegler, E.L. & Kenderian, S.S. CAR-T Cell Therapy: the Efficacy and Toxicity Balance. *Curr Hematol Malig Rep*. 2023 Feb 10;18:9–18.
13. Flugel, C.L., Majzner, R.G., Krenciute, G. et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. *Nat Rev Clin Oncol*. 2023 Nov 23:49–62.
14. Larson, R.C., Maus, M.V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. *Nat Rev Cancer*. 2021 Jan 22:145–61.
15. Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. *Mol Cancer*. 2022 Oct 8;21(1):194.
16. Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current progress in CAR-T Cell Therapy for Solid Tumors. *Int J Biol Sci*. 2019 Oct 07;15(12):2548-60.
17. Dabas P, Danda A. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy. *Med Oncol*. 2023 Aug 22;40(9):275.
18. Ahmad A. CAR-T Cell Therapy. *Int J Mol Sci*. 2020 Jun 17;21(12):4303.
19. Majzner RG, Mackall CL. Tumor Antigen Escape from CAR T-cell Therapy. *Cancer Discov*. 2018 Oct;8(10):1219-26.
20. Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M, Teh B. CAR-T cell therapy and infection: a review. *Expert Rev Anti Infect Ther*. 2021 Jun;19(6):749-58.
21. Lin H, Cheng J, Mu W, Zhou J, Zhu L. Advances in Universal CAR-T Cell Therapy. *Front Immunol*. 2021 Oct 6;12:744823.
22. Pasqui DM, Latorraca CDOC, Pacheco RL, Riera R. CAR-T cell therapy for patients with hematological malignancies. A systematic review. *Eur J Haematol*. 2022 Dec;109(6):601-18.
23. Rejeski K, Jain MD, Shah NN, Perales MA, Subklewe M. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. *Lancet Haematol*. 2024 Jun;11(6):459-70.
24. De Marco RC, Monzo HJ, Ojala PM. CAR T Cell Therapy: A Versatile Living Drug. *Int J Mol Sci*. 2023 Mar 27;24(7):6300.
25. Sermer D, Brentjens R. CAR T-cell therapy: Full speed ahead. *Hematol Oncol*. 2019 Jun;37 Suppl 1:95-100.

26. Yin X, He L, Guo Z. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it. *Immunology*. 2023 Aug;169(4):400-11.
27. Kearl TJ, Furqan F, Shah NN. CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms. *Cancer Metastasis Rev*. 2024 Dec 1;44(1):12.
28. Gu T, Zhu M, Huang H, Hu Y. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. *J Zhejiang Univ Sci B*. 2022 Oct 15;23(10):793-811.
29. Akhoundi M, Mohammadi M, Sahraei SS, Sheykhasan M, Fayazi N. CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. *Cell Oncol (Dordr)*. 2021 Jun;44(3):495-523.
30. Kallam A, Vose JM. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma. *Clin Lymphoma Myeloma Leuk*. 2019 Dec;19(12):751-57.
31. Wang Y, Barrett A, Hu Q. Nanotechnology-Assisted CAR-T-Cell Therapy for Tumor Treatment. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2024 Sep-Oct;16(5):2005.